JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Unraveling the aging-reversal potency of stem cell-derived extracellular vesicles in a rat model of premature cardiac senescence

  • 0Departamento de Bioingeniería, IiSGM, Universidad Carlos III de Madrid, 28911 Leganés, Spain.
Iscience +

|

July 21, 2025

|

July 21, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Cardiosphere-derived cell extracellular vesicles (CDC-EVs) show variable potency. An in vitro assay is proposed to predict CDC-EV efficacy for cardiac rejuvenation, as donor age and cell senescence do not reliably predict potency.

Area Of Science

  • Regenerative Medicine
  • Cardiovascular Biology
  • Cell Biology

Background

  • Cardiosphere-derived cells (CDCs) and their extracellular vesicles (CDC-EVs) show promise for cardiac repair.
  • The therapeutic efficacy of CDC-EVs varies significantly between donors.
  • Identifying predictors of CDC-EV potency is crucial for clinical translation.

Purpose Of The Study

  • To identify reliable predictors of cardiosphere-derived cell extracellular vesicle (CDC-EV) potency.
  • To evaluate the relationship between donor characteristics, CDC senescence, and CDC-EV bioactivity.
  • To establish an in vitro assay for assessing CDC-EV potency.

Main Methods

  • Human CDCs were analyzed for phenotypical and biological properties.
  • CDC-EVs were tested for anti-aging activity using an in vitro matrix assay.
  • Potent (P-EVs) and non-potent (NP-EVs) CDC-EVs were identified and tested in a rat model of cardiac aging.

Main Results

  • Donor age did not correlate with CDC-EV potency.
  • CDC senescence showed a correlation with bioactive properties but was insufficient for predicting potency.
  • P-EVs reduced senescence markers and protected against cardiac aging phenotypes in vivo, while NP-EVs had detrimental effects.

Conclusions

  • CDC-EV anti-aging potency cannot be predicted by donor age or CDC senescence.
  • An in vitro potency assay is proposed as a reliable method for evaluating CDC-EVs prior to clinical application.
  • Standardizing CDC-EV potency assessment is essential for consistent therapeutic outcomes in cardiac regeneration.

Keywords: